Skip to main content

Table 2 Associated factors with intubation in 256 patients with COVID-19 treated with HFNO

From: Predictors of failure with high-flow nasal oxygen therapy in COVID-19 patients with acute respiratory failure: a multicenter observational study

  Odds ratio (95% CI) P value1
Non-respiratory SOFA score 1.78 (1.41-2.35) <0.01
ROX index 0.53 (0.38-0.72) <0.01
pH, per 0.1-unit increase 0.47 (0.24-0.86) 0.03
Leucocyte count, 109/μL 1.07 (1.001-1.13) 0.01
Malignancy 0.14 (0.02-0.88) 0.04
BMI, kg/m2 1.05 (0.97-1.14) 0.23
PaO2/FiO2 (per 10-point increase) 1.04 (0.97-1.11) 0.21
Gender (female) 1.60 (0.73-3.54) 0.24
D-dimer, U/L 1.00 (0.99-1.00) 0.31
APACHE II 0.95 (0.87-1.04) 0.26
Glasgow Coma Scale 0.51 (0.10-1.08) 0.34
Respiratory rate, rpm 0.97 (0.90-1.04) 0.50
Heart rate, bpm (per 10-bpm increase) 1.08 (0.87-1.35) 0.46
Time from symptom onset to ICU admission (per 1-day increase) 1.02 (0.95-1.12) 0.64
SBP, mmHg (per 10-mmHg increase) 0.96 (0.80-1.14) 0.66
PaCO2, mmHg (per 5-mmHg increase) 1.03 (0.87-1.21) 0.76
  1. 1Based on a multivariable logistic regression model after multiple imputation, 2 subjects were excluded for extensive missing data (>50% variables)
  2. CI confidence interval; HFNO high flow nasal oxygen treatment; SOFA Sequential Organ Failure Assessment; SBP systolic blood pressure; BMI body mass index; SpO2 peripheral oxyhemoglobin saturation; ICU intensive care unit; PaO2/FiO2 partial pressure of arterial oxygen to inspiratory oxygen ratio; APACHE Acute Physiology and Chronic Health Evaluation II; PaCO2 partial pressure of carbon dioxide; AIC Akaike information criterion